Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.

Palmer J, Williams K, Inamoto Y, Chai X, Martin PJ, Tomas LS, Cutler C, Weisdorf D, Kurland BF, Carpenter PA, Pidala J, Pavletic SZ, Wood W, Jacobsohn D, Arai S, Arora M, Jagasia M, Vogelsang GB, Lee SJ.

Biol Blood Marrow Transplant. 2014 Mar;20(3):337-44. doi: 10.1016/j.bbmt.2013.11.025. Epub 2013 Dec 4.

2.

Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease.

Palmer J, Chai X, Pidala J, Inamoto Y, Martin PJ, Storer B, Pusic I, Flowers ME, Arora M, Pavletic SZ, Lee SJ.

Blood. 2016 Jan 7;127(1):160-6. doi: 10.1182/blood-2015-08-662874. Epub 2015 Nov 2.

3.

Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.

Inagaki J, Moritake H, Nishikawa T, Hyakuna N, Okada M, Suenobu S, Nagai K, Honda Y, Shimomura M, Fukano R, Noguchi M, Kurauchi K, Tanioka S, Okamura J.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1973-80. doi: 10.1016/j.bbmt.2015.07.025. Epub 2015 Jul 31.

4.

Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium.

Pidala J, Chai X, Martin P, Inamoto Y, Cutler C, Palmer J, Weisdorf D, Pavletic S, Arora M, Jagasia M, Jacobsohn D, Lee SJ.

Biol Blood Marrow Transplant. 2013 Jun;19(6):967-72. doi: 10.1016/j.bbmt.2013.03.014. Epub 2013 Mar 27.

5.

Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.

Moon JH, Sohn SK, Lambie A, Ellis L, Hamad N, Uhm J, Gupta V, Lipton JH, Messner HA, Kuruvilla J, Kim D.

Biol Blood Marrow Transplant. 2014 Apr;20(4):556-63. doi: 10.1016/j.bbmt.2014.01.010. Epub 2014 Jan 18.

6.

NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHD.

Curtis LM, Grkovic L, Mitchell SA, Steinberg SM, Cowen EW, Datiles MB, Mays J, Bassim C, Joe G, Comis LE, Berger A, Avila D, Taylor T, Pulanic D, Cole K, Baruffaldi J, Fowler DH, Gress RE, Pavletic SZ.

Bone Marrow Transplant. 2014 Dec;49(12):1513-20. doi: 10.1038/bmt.2014.188. Epub 2014 Aug 25.

PMID:
25153693
7.

National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis.

Baird K, Steinberg SM, Grkovic L, Pulanic D, Cowen EW, Mitchell SA, Williams KM, Datiles MB, Bishop R, Bassim CW, Mays JW, Edwards D, Cole K, Avila DN, Taylor T, Urban A, Joe GO, Comis LE, Berger A, Stratton P, Zhang D, Shelhamer JH, Gea-Banacloche JC, Sportes C, Fowler DH, Gress RE, Pavletic SZ.

Biol Blood Marrow Transplant. 2013 Apr;19(4):632-9. doi: 10.1016/j.bbmt.2013.01.013. Epub 2013 Jan 20.

8.

Validation of measurement scales in ocular graft-versus-host disease.

Inamoto Y, Chai X, Kurland BF, Cutler C, Flowers ME, Palmer JM, Carpenter PA, Heffernan MJ, Jacobsohn D, Jagasia MH, Pidala J, Khera N, Vogelsang GB, Weisdorf D, Martin PJ, Pavletic SZ, Lee SJ; Chronic GVHD Consortium.

Ophthalmology. 2012 Mar;119(3):487-93. doi: 10.1016/j.ophtha.2011.08.040. Epub 2011 Dec 6.

9.

Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria.

Sato T, Ichinohe T, Kanda J, Yamashita K, Kondo T, Ishikawa T, Uchiyama T, Takaori-Kondo A.

Int J Hematol. 2011 Apr;93(4):532-541. doi: 10.1007/s12185-011-0820-0. Epub 2011 Apr 5.

PMID:
21465116
10.

Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.

Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, Pidala J, Olivieri A, Martin PJ, Przepiorka D, Pusic I, Dignan F, Mitchell SA, Lawitschka A, Jacobsohn D, Hall AM, Flowers ME, Schultz KR, Vogelsang G, Pavletic S.

Biol Blood Marrow Transplant. 2015 Jun;21(6):984-99. doi: 10.1016/j.bbmt.2015.02.025. Epub 2015 Mar 19.

11.

The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality.

Pidala J, Kim J, Anasetti C, Nishihori T, Betts B, Field T, Perkins J.

Haematologica. 2011 Nov;96(11):1678-84. doi: 10.3324/haematol.2011.049841. Epub 2011 Jul 26.

12.

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews.

Merkel EC, Mitchell SA, Lee SJ.

Biol Blood Marrow Transplant. 2016 Apr;22(4):752-758. doi: 10.1016/j.bbmt.2015.12.026. Epub 2016 Jan 2.

13.

Analysis of gastrointestinal and hepatic chronic graft-versus-host [corrected] disease manifestations on major outcomes: a chronic graft-versus-host [corrected] disease consortium study.

Pidala J, Chai X, Kurland BF, Inamoto Y, Flowers ME, Palmer J, Khera N, Jagasia M, Cutler C, Arora M, Vogelsang G, Lee SJ.

Biol Blood Marrow Transplant. 2013 May;19(5):784-91. doi: 10.1016/j.bbmt.2013.02.001. Epub 2013 Feb 6. Erratum in: Biol Blood Marrow Transplant. 2014 Feb;20(2):290.

14.

Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria.

Arai S, Jagasia M, Storer B, Chai X, Pidala J, Cutler C, Arora M, Weisdorf DJ, Flowers ME, Martin PJ, Palmer J, Jacobsohn D, Pavletic SZ, Vogelsang GB, Lee SJ.

Blood. 2011 Oct 13;118(15):4242-9. doi: 10.1182/blood-2011-03-344390. Epub 2011 Jul 26.

15.

Predicting chronic GVHD outcomes: are we there yet?

Jacobsohn DA.

Blood. 2016 Jan 7;127(1):14-5. doi: 10.1182/blood-2015-11-681072.

16.

The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation.

Thepot S, Zhou J, Perrot A, Robin M, Xhaard A, de Latour RP, Ades L, Ribaud P, Petropoulou AD, Porcher R, Socié G.

Leukemia. 2010 Nov;24(11):1852-8. doi: 10.1038/leu.2010.187. Epub 2010 Sep 9.

PMID:
20827288
17.

Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria.

Jagasia M, Giglia J, Chinratanalab W, Dixon S, Chen H, Frangoul H, Engelhardt B, Goodman S, Greer J, Kassim A, Morgan D, Ruffner K, Schuening F.

Biol Blood Marrow Transplant. 2007 Oct;13(10):1207-15. Epub 2007 Aug 24.

18.

Relationship of body mass index and arm anthropometry to outcomes after pediatric allogeneic hematopoietic cell transplantation for hematologic malignancies.

Hoffmeister PA, Storer BE, Macris PC, Carpenter PA, Baker KS.

Biol Blood Marrow Transplant. 2013 Jul;19(7):1081-6. doi: 10.1016/j.bbmt.2013.04.017. Epub 2013 Apr 25.

19.

Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.

Devillier R, Fürst S, El-Cheikh J, Castagna L, Harbi S, Granata A, Crocchiolo R, Oudin C, Mohty B, Bouabdallah R, Chabannon C, Stoppa AM, Charbonnier A, Broussais-Guillaumot F, Calmels B, Lemarie C, Rey J, Vey N, Blaise D.

Biol Blood Marrow Transplant. 2014 Mar;20(3):370-4. doi: 10.1016/j.bbmt.2013.11.030. Epub 2013 Dec 4.

20.

Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease.

Russell JA, Duan Q, Chaudhry MA, Savoie ML, Balogh A, Turner AR, Larratt L, Storek J, Bahlis NJ, Brown CB, Quinlan D, Geddes M, Zacarias N, Daly A, Duggan P, Stewart DA.

Biol Blood Marrow Transplant. 2008 Aug;14(8):888-95. doi: 10.1016/j.bbmt.2008.05.010.

Supplemental Content

Support Center